Can a Three-Drug combo outsmart High-Risk CLL?

NCT ID NCT07738887

Not yet recruiting Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 alterations. These genetic changes make the disease harder to treat and more likely to progress. The study will give participants the drugs in a sequence, starting with ibrutinib alone, then adding venetoclax, and finally epcoritamab, with the goal of achieving deep remissions (complete response with undetectable minimal residual disease) while using a fixed treatment duration. The trial will also monitor safety and tolerability in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination of three drugs: ibrutinib (a targeted therapy), venetoclax (a BCL-2 inhibitor), and epcoritamab (a bispecific antibody that helps immune cells attack cancer).
What this could lead to: If successful, this combination could offer a more effective, fixed-duration treatment for a high-risk form of CLL, potentially leading to deeper and longer-lasting remissions without continuous therapy.
What could go wrong: This is a phase 2 trial with a small number of participants, so results may not be conclusive. The triple-drug regimen may cause significant side effects, and not all patients may respond as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

AP-HP Pitié Salpêtrière

Paris, 75013, France
AP-HP Saint-Louis

Paris, 75010, France
CHU DE Montpellier

Montpellier, 34090, France
CHU d'ANGERS

Angers, 49100, France
CHU de Bordeaux HOPITAL HAUT-LEVEQUE

Pessac, 33000, France
Centre Antoine Lacassagne

Nice, 06100, France
Ch Du Mans-Centre de Cancerologie de La Sarthe

Le Mans, 72100, France
Ch Metropole Savoie

Chambéry, 73000, France
Ch Mont-de-Marsan - Hopital de Layné

Mont-de-Marsan, 40000, France
Ch Rene Dubos

Pontoise, 95300, France
Chd de Vendee

La Roche-sur-Yon, 85000, France
Chr Metz-Thionville - Hopital de Mercy

Metz, 57530, France
Chru de Strasbourg

Strasbourg, 67000, France
Chu Estaing

Clermont-Ferrand, 63100, France
Chu Lyon-Sud

Lyon, 69310, France
Chu Pontchaillou

Rennes, 35000, France
Chu Ucl Namur - Site Godinne

Namur, 5000, Belgium
Chu de Lille - Hopital Claude Huriez

Lille, 59000, France
Chu de Nantes

Nantes, 44000, France
Chu de Poitiers - Hopital de La Miletrie

Poitiers, 86000, France
Gustave Roussy Cancer Campus Grand Paris

Paris, 94800, France
HELORA - Hôpital de La Louvière Site Jolimont

La Louvière, 7100, Belgium
Institut D'Hematologie de Basse Normandie

Caen, 14000, France
Institut Jules Bordet

Brussels, 1070, Belgium
Institut Paoli Calmettes

Marseille, 13009, France
Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne

Saint-Etienne, 42270, France
Iuct Oncopole

Toulouse, 31100, France
U.Z. LEUVEN - Campus GASTHUISBERG

Leuven, 3001, Belgium
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.